Found: 15
Select item for more details and to access through your institution.
Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.
- Published in:
- Head & Neck, 2008, v. 30, n. 6, p. 790, doi. 10.1002/hed.20770
- By:
- Publication type:
- Article
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.
- Published in:
- Nature Communications, 2018, v. 9, n. 1, p. 1, doi. 10.1038/s41467-018-07334-3
- By:
- Publication type:
- Article
Multimodal platform for assessing drug distribution and response in clinical trials.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 1, p. 64, doi. 10.1093/neuonc/noab197
- By:
- Publication type:
- Article
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 12, p. 2042, doi. 10.1093/neuonc/noab133
- By:
- Publication type:
- Article
Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 11, p. 1458, doi. 10.1093/neuonc/noz129
- By:
- Publication type:
- Article
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 9, p. 1141, doi. 10.1093/neuonc/noz090
- By:
- Publication type:
- Article
INFLUENCE OF DRUG DELIVERY ON THERAPEUTIC BENEFIT IN GBM–CDK4 AND MDM2 INHIBITOR COMPARISON IN FLANK VERSUS ORTHOTOPIC MODELS AND COMPARISON OF BRAIN PENETRANT VERSUS IMPENETRANT PI3K/MTOR INHIBITORS.
- Published in:
- Neuro-Oncology, 2014, v. 16, n. suppl_3, p. iii33, doi. 10.1093/neuonc/nou208.40
- By:
- Publication type:
- Article
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
- Published in:
- Neuro-Oncology, 2013, v. 15, n. 6, p. 735, doi. 10.1093/neuonc/not010
- By:
- Publication type:
- Article
p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
- Published in:
- Neuro-Oncology, 2012, v. 14, n. 7, p. 870, doi. 10.1093/neuonc/nos114
- By:
- Publication type:
- Article
WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models.
- Published in:
- Neuro-Oncology Advances, 2023, v. 5, n. 1, p. 1, doi. 10.1093/noajnl/vdad066
- By:
- Publication type:
- Article
Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
- Published in:
- Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac130
- By:
- Publication type:
- Article
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2018.00670
- By:
- Publication type:
- Article
RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 8, p. 1261, doi. 10.1093/neuonc/noac051
- By:
- Publication type:
- Article
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 3, p. 384, doi. 10.1093/neuonc/noab162
- By:
- Publication type:
- Article
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article